Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003597 · ClinicalTrials.gov registry record · Phase 1
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00003597 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 16 participants.
The verdict
NCT00003597, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of colony-stimulating factors in treating children who have recurrent or refractory solid tumors and who are receiving chemotherapy.
Interventions
- DRUG carboplatin
- BIOLOGICAL G-CSF
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL recombinant human thrombopoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 1998-11 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003597
The ClinicalTrials.gov registry entry for NCT00003597 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003597 about?
NCT00003597 is a clinical study titled "Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system r...
What is the current status of trial NCT00003597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 1998-11. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00003597?
The interventions under investigation include: carboplatin (DRUG), G-CSF (BIOLOGICAL), etoposide (DRUG), ifosfamide (DRUG), recombinant human thrombopoietin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003597?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.